ANI Pharmaceuticals reports stronger-than-expected Q1 earnings and revenue, driven by a 24.1% year-over-year increase in adjusted EBITDA.
ANI Pharmaceuticals posted first-quarter non-GAAP earnings per share of $2.05, exceeding estimates by $0.75, as revenue rose 20.5% year-over-year to $237.5 million. The company also reported GAAP net income of $29.5 million for common shareholders.
Adjusted non-GAAP EBITDA reached $63.0 million, up 24.1% from the same period last year, surpassing consensus projections by $29.87 million. The results reflect continued growth in core revenue streams.
The company did not disclose immediate market reactions in the release.